Showing results (671-680 of 692) with videos related to
Sort By:
Pageof 70
Hepatology (Baltimore, Md.)|October 8, 2025
Association between longitudinal weight change and clinical outcome in individuals with MASLDYu Shi, Ruoqi Zhou, Seung Up Kim, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2025
Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLDXiao-Dong Zhou, Qin-Fen Chen, Seung Up Kim, et al.Gastroenterology|March 20, 2025
From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease From a Dynamic PerspectiveWen-Yue Liu, Shanshan Huang, Hongsheng Ji, et al.Journal of Gastrointestinal and Liver Diseases : JGLD|December 26, 2025
Diagnostic Performance of LIVERFASt as a Non-invasive Liver Fibrosis Test: Data from Three Cohorts of Patients with Metabolic Dysfunction-associated Steatotic Liver DiseaseNaim Alkhouri, Parvez Mantry, Humberto C Gonzalez, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 8, 2026
Progression of Liver Fibrosis and Liver-Related Event Risk in MASLD at High Cardiovascular RiskXiao-Dong Zhou, Qin-Fen Chen, Seung Up Kim, et al.Gut|June 20, 2025
Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver diseaseJimmy Che-To Lai, Boyu Yang, Hye Won Lee, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 20, 2026
Machine Learning Prediction of Liver Fibrosis in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)Salvatore Petta, Grazia Pennisi, Ciro Celsa, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 1, 2026
ONE-YEAR CHANGES IN LSM, BUT NOT IN ALT AND CAP, PREDICT LONG-TERM LIVER OUTCOMES IN PATIENTS WITH MASLDGrazia Pennisi, Giuseppe Infantino, Gabriele Di Maria, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 11, 2025
A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort StudyHo Soo Chun, Minjong Lee, Hye Ah Lee, et al.Hepatology (Baltimore, Md.)|December 16, 2025
Cardiovascular-Kidney-Metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLDXiao-Dong Zhou, Qin-Fen Chen, Qiong-Yue Fan, et al.Pageof 70